Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD 36.8 million) Series A financing round led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing shareholders Kingray Capital and TigerYeah Capital.
Financing Overview
| Parameter | Detail |
|---|---|
| Company | Shanghai Immunocan Biotech Co., Ltd. |
| Financing Round | Series A |
| Total Amount | RMB 250 million (USD 36.8 million) |
| Lead Investor | Vivo Capital |
| Participating Investors | Gold Mine Multi Family Office, Kingray Capital, TigerYeah Capital |
| Primary Focus | Next-generation antibody discovery platforms based on gene editing technology |
Fund Allocation Strategy
Proceeds will be strategically deployed across multiple platform development initiatives:
| Initiative | Strategic Objective |
|---|---|
| Gene-edited animal platforms | Accelerate continuous R&D of proprietary transgenic models |
| Fully human antibody rabbit platform | Advance commercialization of established rabbit-derived antibody technology |
| AI-driven antibody drug screening platform | Establish machine learning-enhanced discovery capabilities |
| Scaffold antibodies for complex targets | Develop novel binding formats for challenging epitopes |
| General corporate operations & team expansion | Support infrastructure growth and talent acquisition |
Proprietary Technology Portfolio
MASIRT Platform Innovation
The company’s core Massive-fragment Across Species In situ Replacement Technology (MASIRT) represents a breakthrough in gene editing capabilities:
| Technical Feature | Competitive Advantage |
|---|---|
| Linear artificial chromosome delivery | Significantly enhanced gene fragment loading capacity |
| Megabase-scale DNA replacement | Single-operation large-fragment editing capability |
| Reduced editing cycles | Drastic improvement in development timeline efficiency |
| Species barrier elimination | Successful cross-species application without limitations |
| Multi-species validation | Proven functionality across diverse animal models |
Diversified Antibody Discovery Platforms
Immunocan Bio has developed a comprehensive portfolio of proprietary platforms:
| Platform | Unique Characteristics | IP Protection |
|---|---|---|
| Fully human mouse platform | Established transgenic mouse model | China, Europe, USA, Japan |
| Fully human rabbit platform | Enhanced diversity and affinity maturation | China, Europe, USA, Japan |
| Rabbit-derived single heavy-chain antibody platform | Simplified format with improved tissue penetration | China, Europe, USA, Japan |
| ImmuAlpaca (alpaca-mouse) platform | Novel hybrid species combining advantageous traits | China, Europe, USA, Japan |
Strategic Market Positioning
Next-Generation Antibody Discovery
The company addresses critical industry challenges in therapeutic antibody development:
- Target complexity: Scaffold antibodies designed for difficult-to-drug targets
- Diversity limitations: Multi-species platforms provide broader antibody repertoire
- Development efficiency: MASIRT technology reduces timeline from target to lead candidate
- Format innovation: Single-domain and conventional antibodies from same platform family
Competitive Differentiation
- Integrated approach: Combines gene editing, multi-species platforms, and AI-driven screening
- IP moat: Comprehensive patent protection across major pharmaceutical markets
- Platform breadth: Unusual combination of mouse, rabbit, and alpaca-derived technologies
- Technical leadership: MASIRT represents significant advancement over conventional gene editing
Industry Context & Investment Rationale
Antibody Discovery Market Evolution
- Platform competition: Intense race among biotech companies to develop superior discovery technologies
- Big pharma demand: Major pharmaceutical companies increasingly outsourcing antibody discovery to specialized platforms
- Technical innovation: Shift toward gene-edited animals with enhanced human-like immune systems
- AI integration: Growing adoption of machine learning in antibody optimization and screening
Chinese Biotech Ecosystem
- Platform company emergence: China developing sophisticated biologics discovery infrastructure
- International competitiveness: Chinese platforms increasingly competitive with Western counterparts
- Investment momentum: Strong venture capital interest in next-generation biologics technologies
- Global ambition: Companies like Immunocan targeting international partnerships and licensing deals
The Series A financing validates Immunocan’s integrated platform strategy and positions the company to become a leading global provider of next-generation antibody discovery capabilities, combining cutting-edge gene editing with multi-species diversity and AI-enhanced screening.-Fineline Info & Tech
